title: Brachytherapy treatment planning commissioning: effect of the election of proper bibliography and finite size of TG-43 input data on standard treatments.
abstract: The aim of this work is to evaluate the performance of a commercial brachytherapy treatment planning system (TPS) with TG-43 Vendors Input Data (VID), analyze possible discrepancies with respect to a proper reference source and its implications for standard treatments, and judge the effectiveness of certain widespread recommended quality controls to find potential errors related with the interpolations of TG-43 VID tables. The TPS evaluated was a BrachyVision 8.6 loaded with TG-43 VID for a VariSource high-dose-rate 192Ir source (Vs2000). The reference data chosen were the TG-43 data published in the literature. In the first step, we compared TG-43 VID with respect to the chosen reference data. Next, we used percent dose-rate differences in a point array matrix to compare the outcomes of the TPS on standard treatment setup with respect to an in-house developed program (MATLAB R2009a-based) loaded with the chosen full TG-43 reference data. The cases with major discrepancies were evaluated using the gamma-index analysis. The comparison with the reference data indicated a lack of sample in the angles between near to the tip (between 165 < θ < 180) and cable (0 < θ < 15) of the F(r,θ)(VID), which causes a dose underestimation of approximately 17% in the investigated points due to inaccurate interpolations. The differences over 2% encompassed approximately 17% of the surrounding source volume. These results have special relevance in treatment using one applicator with a few dwell steps or in Fletcher treatments where 10% dose underestimates were identified within the tumor or in organs at risk, respectively. Our results suggest that the differences found in the TPS under study are created by a lack of information on the angles in high-gradient zones in the F(r,θ)(VID), which generates important differences in dosimetric results. In contrast, the gamma analysis shows very good results (between 90% and 100% of passed points) in the analyzed treatments (one dwell and Fletcher). Further studies are required to exclude the possibility of finding noticeable effects in the DVH of treatment plans caused by the discrepancies here described. To achieve more strict control over the TPS dose-rate calculation, we recommend using QA test thinking in a source with nonaxial symmetry, adding a control point on the angles of the high-dose gradient zones (e.g., between 0° and 15° and between 165° and 180°). More studies are required to achieve full understanding of the clinical implication of such discrepancies.
authors.affiliation: Centro Oncológico de Antofagasta. cvalcort@gmail.com.
authors.forename: Christian N
authors.initials: CN
authors.lastname: Valdés
authors.forename: Gustavo H
authors.initials: GH
authors.lastname: Píriz
authors.forename: Enrrique
authors.initials: E
authors.lastname: Lozano
mesh_terms: D001918:Brachytherapy / Q000379:methods / Q000592:standards*; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008962:Models, Theoretical; D009369:Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods / Q000592:standards*; D012015:Reference Standards
chemical_list: D007496:Iridium Radioisotopes